MACE Risk Score Calculation Using ST2 and NT-proBNP Biomarkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clinical evaluation for determining disease severity and predicting major adverse cardiac events (MACE) often relies on subjective assessments, lacking objective biomarkers to guide treatment decisions and risk stratification.
Innovation Solution
The use of serum ST2 levels in combination with natriuretic peptides, such as NT-proBNP, to calculate a MACE risk score through a formula that compares ST2 ratios and weighted logarithm of NT-proBNP levels, providing a quantitative assessment of cardiac event risk within specific time frames.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If clinical evaluation relies on physician's subjective assessment or gut feeling, then the evaluation process is simple and quick, but the accuracy and objectivity of disease severity determination and MACE prediction deteriorates
Solution Approach 1:
The patent transforms the evaluation from subjective clinical judgment to objective quantitative measurement by using biomarker levels (ST2 and NT-proBNP) as measurable parameters. The formula X=(ST2 T1/ST2 T0)+α ln(NT-proBNP T1) converts biological parameters into a standardized risk score, enabling precise and objective MACE prediction while maintaining relatively simple implementation through routine blood tests.
2Reliability
If no objective biomarkers are used for risk stratification, then the treatment decision process is straightforward, but the ability to make informed treatment decisions and improve patient care deteriorates
Solution Approach 1:
The patent introduces biomarkers ST2 and NT-proBNP as intermediary substances that mediate between the patient's physiological state and the clinical decision-making process. These biomarkers serve as objective intermediaries that translate complex cardiac pathophysiology into quantifiable risk scores, enabling reliable treatment decisions without requiring physicians to directly interpret complex clinical presentations.
3Productivity
If clinical assessment alone is used to determine disease severity, then healthcare resource allocation is simple, but the optimization of resource allocation and reduction of healthcare costs deteriorates
Solution Approach 1:
The patent replaces the mechanical/subjective system of clinical assessment with a biochemical measurement system. By substituting physician intuition with objective biomarker measurements and mathematical formulas, the system preserves critical disease severity information that would otherwise be lost, enabling optimized resource allocation based on actual patient risk rather than subjective evaluation.
Data Source
AI summary
Measurement of circulating ST2 and natriuretic peptide (e.g., NT-proBNP) concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, transplantation, and heart failure.